Literature DB >> 16845658

Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.

Annette Staebler1, Bianca Karberg, Juliane Behm, Petra Kuhlmann, Ulrike Neubert, Hartmut Schmidt, Eberhard Korsching, Horst Bürger, Ralph Lelle, Ludwig Kiesel, Werner Böcker, Ie-Ming Shih, Olaf Buchweitz.   

Abstract

In this study, we describe characteristic chromosomal alterations in a consecutive series of 96 serous ovarian tumors by comparative genomic hybridization. We analyze their association with different pathways of progression, histological grade, and clinical outcome. The most striking difference between low-grade and high-grade serous carcinomas was seen in a higher incidence of chromosomal gains at 3q and 20q and losses of 13q in the high-grade carcinomas. In addition, high-level amplifications were significantly more frequent in high-grade carcinomas, specifically involving regions on 3q and 8q. Chromosomal amplifications of 19p and 19q and losses of 4q and 5q were among the most frequent changes found in both low-grade and high-grade carcinomas, distinguishing them from borderline tumors, which had very few recurrent alterations. The most significant impact on survival of patients with invasive carcinomas Stage II-IV was observed for high-level amplifications of regions on 8q (mean overall survival (OS) 69 versus 27 months, P = 0.0006). Interestingly, low-level gains on 8q do not show any impact compared to cases with no alteration. Surprisingly, chromosomal losses on 5q had a protective impact (mean OS 36 versus 76 months, P = 0.0007). Combination of both parameters resulted in two risk groups. Low risk: loss on 5q, no amplification on 8q (mean OS 84 months); high risk: no loss on 5q, amplification on 8q (mean OS 26 months). This difference is even more pronounced, if only cases with residual tumor of less than 2 cm are included, resulting in a 5-year survival of 100% and 0% (P = 0.0005). (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16845658     DOI: 10.1002/gcc.20356

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer.

Authors:  Tineke E Buffart; Beatriz Carvalho; Nicole C T van Grieken; Wessel N van Wieringen; Marianne Tijssen; Elma Meershoek-Klein Kranenbarg; Henk M W Verheul; Heike I Grabsch; Bauke Ylstra; Cornelis J H van de Velde; Gerrit A Meijer
Journal:  Oncologist       Date:  2012-04-24

Review 2.  [Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis].

Authors:  A Staebler
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

3.  [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy].

Authors:  A Staebler; J Diebold
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

4.  Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Authors:  Amir A Jazaeri; Jennifer L Bryant; Hong Park; Hui Li; Neetu Dahiya; Mark H Stoler; James Stuart Ferriss; Anindya Dutta
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

5.  Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Authors:  Dariush Etemadmoghadam; Anna deFazio; Rameen Beroukhim; Craig Mermel; Joshy George; Gad Getz; Richard Tothill; Aikou Okamoto; Maria B Raeder; Paul Harnett; Stephen Lade; Lars A Akslen; Anna V Tinker; Bianca Locandro; Kathryn Alsop; Yoke-Eng Chiew; Nadia Traficante; Sian Fereday; Daryl Johnson; Stephen Fox; William Sellers; Mitsuyoshi Urashima; Helga B Salvesen; Matthew Meyerson; David Bowtell
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

6.  High-level amplification at 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer.

Authors:  J Pärssinen; T Kuukasjärvi; R Karhu; A Kallioniemi
Journal:  Br J Cancer       Date:  2007-03-13       Impact factor: 7.640

7.  The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells.

Authors:  Brigitte L Thériault; Paulina Cybulska; Patricia A Shaw; Brenda L Gallie; Marcus Q Bernardini
Journal:  J Ovarian Res       Date:  2014-12-21       Impact factor: 4.234

Review 8.  Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice.

Authors:  Anliang Dong; Yan Lu; Bingjian Lu
Journal:  J Cancer       Date:  2016-07-05       Impact factor: 4.207

9.  Kinesin family member 14 in human oral cancer: A potential biomarker for tumoral growth.

Authors:  Isao Miyamoto; Atsushi Kasamatsu; Masanobu Yamatoji; Dai Nakashima; Kengo Saito; Morihiro Higo; Yosuke Endo-Sakamoto; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  Biochem Biophys Rep       Date:  2015-07-15

10.  Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.

Authors:  Mei Zeng; Nicholas P Kwiatkowski; Tinghu Zhang; Behnam Nabet; Mousheng Xu; Yanke Liang; Chunshan Quan; Jinhua Wang; Mingfeng Hao; Sangeetha Palakurthi; Shan Zhou; Qing Zeng; Paul T Kirschmeier; Khyati Meghani; Alan L Leggett; Jun Qi; Geoffrey I Shapiro; Joyce F Liu; Ursula A Matulonis; Charles Y Lin; Panagiotis A Konstantinopoulos; Nathanael S Gray
Journal:  Elife       Date:  2018-11-13       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.